Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Lenacapavir/islatravir combo carries mechanistic rationale Mixed oral/subQ regimens don’t provide additional convenience ...

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy. The two studies – IMPOWER 22 ...

One patient on islatravir/lenacapavir did show a detectable viral load of more than 50 copies/mL at 24 weeks, but fell below that threshold at 30 weeks, according to Gilead and MSD, and two ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

Copyright: © 2022 Published by Elsevier Ltd. In September, Merck Sharp & Dohme (MSD) announced that HIV treatment trials of islatravir would resume. The drug, a ...

Switching to doravirine plus islatravir was shown to be non-inferior to continuing a bictegravir-based ART regimen in virologically suppressed participants without previous virological failure.

I am very excited to hear that Merck is restarting HIV research with Islatravir. Due to safety concerns, Merck suspended clinical trials of this remarkable anti-HIV drug candidate last December.